Metabolic-associated fatty liver disease

1. Geriatric Nutritional Risk Index predicts metabolic-associated fatty liver disease in humans (predicting occurrence of MAFLD) (AUC = 0.909).

   “Overall, the predictive performance of GNRI was superior to that of CONUT (AUC = 0.909) and PNI (AUC = 0.909)”

   Humanspredicting occurrence of MAFLD

   Analysis of the correlation and predictive performance of GNRI, CONUT, and PNI with MAFLD in Chinese adult physical examination population

   Frontiers in nutrition·Apr 21, 2026

2. Geriatric Nutritional Risk Index is linked with a higher risk of metabolic-associated fatty liver disease in humans (multivariable models, Q4 vs Q1) (OR 7.01, 95% CI 5.08-9.67).

   “the risk of developing MAFLD in the fourth quartile of GNRI and PNI was 7.01 times (OR = 7.01, 95% CI: 5.08-9.67) and 1.82 times (OR = 1.82, 95% CI: 1.51-2.19) that of the first quartile”

   Humansmultivariable models, Q4 vs Q1

   Analysis of the correlation and predictive performance of GNRI, CONUT, and PNI with MAFLD in Chinese adult physical examination population

   Frontiers in nutrition·Apr 21, 2026

More on Geriatric Nutritional Risk Index

1. Intermittent fasting lowers the risk of metabolic-associated fatty liver disease in humans (versus daily calorie restriction eating) (33.3% vs. 63.0%).

   “Fewer percentage of patients were diagnosed with fatty liver via upper abdominal ultrasound in the 5:2 IF diet group compared to the daily calorie restriction eating group (33.3% vs. 63.0%, p = 0.029).”

   Human trialversus daily calorie restriction eating12-week periodn = 54

   Effect of 5:2 intermittent fasting diet versus daily calorie restriction eating on metabolic-associated fatty liver disease-a randomized controlled trial

   Frontiers in nutrition·Aug 20, 2024

2. Intermittent fasting lowers the risk of metabolic-associated fatty liver disease in humans (metabolic-associated fatty liver disease) (33.3% vs. 63.0%, p = 0.029).

   “fewer percentage of patients were diagnosed with fatty liver via upper abdominal ultrasound in the 5:2 intermittent fasting diet group (33.3% vs. 63.0%, p = 0.029)”

   Human trialmetabolic-associated fatty liver disease12 weeksn = 60

   Effect of 5:2 intermittent fasting diet versus daily calorie restriction eating on metabolic-associated fatty liver disease-a randomized controlled trial

   Frontiers in nutrition·Aug 20, 2024

More on Intermittent fasting

1. 25-hydroxyvitamin D is associated with metabolic-associated fatty liver disease in humans (r = -0.242; P < 0.05).

   “Significant inverse correlations were observed between vitamin D levels and AC (r = -0.238) and MAFLD (r = -0.242) (both P < 0.05).”

   Humanswithout established atherosclerotic cardiovascular disease; association attenuated after adjustment for body mass index but remained significant with waist circumference adjustmentn = 303

   Ectopic Adipose Tissue Depots and Metabolic-Associated Fatty Liver Disease: Relationships With Vitamin D

   Journal of clinical medicine research·Oct 23, 2026

More on 25-hydroxyvitamin D

1. Frailty and metabolic syndrome is linked with a higher risk of metabolic-associated fatty liver disease in humans (compared with neither frailty nor MetS) (HR 2.92 (2.45-3.47)).

   “HR and 95% confidence intervals for Group 4 (both frailty and MetS) was 2.92 (2.45-3.47) for MAFLD”

   Humanscompared with neither frailty nor MetS12.7 years

   Association of frailty and metabolism with multi-state model in fatty liver disease, diabetes mellitus and all-cause mortality

   Diabetology & metabolic syndrome·Jun 23, 2026

1. Prognostic nutritional index is linked with a higher risk of metabolic-associated fatty liver disease in humans (multivariable models, Q4 vs Q1) (OR 1.82, 95% CI 1.51-2.19).

   “the risk of developing MAFLD in the fourth quartile of GNRI and PNI was 7.01 times (OR = 7.01, 95% CI: 5.08-9.67) and 1.82 times (OR = 1.82, 95% CI: 1.51-2.19) that of the first quartile”

   Humansmultivariable models, Q4 vs Q1

   Analysis of the correlation and predictive performance of GNRI, CONUT, and PNI with MAFLD in Chinese adult physical examination population

   Frontiers in nutrition·Apr 21, 2026

More on Prognostic nutritional index

1. Metabolic-associated fatty liver disease is associated with body mass index in humans (at baseline in participants with type 2 diabetes and obesity).

   “The prevalence of some comorbidities (such as metabolic associated fatty liver disease, gout/hyperuricemia) showed strong association of BMI.”

   Human trialat baseline in participants with type 2 diabetes and obesityn = 349

   Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial

   Contemporary clinical trials·Nov 17, 2025

1. random forest model predicts metabolic-associated fatty liver disease in silico (AUC 0.892 (95% CI: 0.870-0.914)).

   “the Random Forest (RF) model performed best, achieving an area under the curve (AUC) of 0.892 (95% CI: 0.870-0.914) in the validation cohort.”

   In silico

   Predicting the risk of metabolic-associated fatty liver disease in the elderly population in China: construction and evaluation of interpretable machine learning models

   Frontiers in medicine·Oct 20, 2025

1. Metabolic-associated fatty liver disease is linked with a higher risk of mortality in humans (adjusted for age, sex, race, marital status, education, and smoking) (aHR 1.152, 95% CI 1.070-1.241).

   “MAFLD (aHR 1.152, 95% CI 1.070-1.241) and sarcopenia (aHR 1.123, 95% CI 1.042-1.210) were related to increased all-cause mortality in MAFLD”

   Humansadjusted for age, sex, race, marital status, education, and smoking23.7 ± 7.62 yearsn = 13,692

   Metabolic associated fatty liver disease and sarcopenia additively increase mortality: a real-world study

   Nutrition & diabetes·Nov 15, 2023

1. Creatinine-to-cystatin C ratio is associated with metabolic-associated fatty liver disease in humans (OR 1.340, 95%CI 1.077-1.669, P=0.009).

   “In cross-sectional and prospective analyses, participants in CCR tertile 1 had the highest MAFLD risk”

   Humansn = 368,634

   Lower creatinine to cystatin C ratio is associated with an increased risk of MAFLD: A cross-sectional and prospective study of 368,634 UK Biobank participants

   Research Square·Jul 21, 2023Preprint

More on Creatinine-to-cystatin C ratio

1. Endometrial thickness is associated with metabolic-associated fatty liver disease in humans (Postmenopausal women; endometrial thickness ≥5 mm; adjusted for age) (Age-adjusted OR 1.383, 95% CI 1.109–1.724 for endometrial thickness ≥5 mm).

   “≥5 mm (OR=1.383, 95% CI: 1.109-1.724) achieved statistical significance, respectively.”

   HumansPostmenopausal women; endometrial thickness ≥5 mm; adjusted for ageendometriumfemalesn = 8,594

   Relationship between the Metabolic Associated Fatty Liver Disease and Endometrial Thickness in Postmenopausal Women: A Cross-sectional Study in China

   International journal of medical sciences·Jun 22, 2021

More on Endometrial thickness